Literature DB >> 20551939

Risk factors for neoplasia in inflammatory bowel disease patients with pancolitis.

Vivianne Bergeron1, Ariane Vienne, Harry Sokol, Philippe Seksik, Isabelle Nion-Larmurier, Agnès Ruskone-Fourmestraux, Magali Svrcek, Laurent Beaugerie, Jacques Cosnes.   

Abstract

OBJECTIVES: Colorectal cancer (CRC), developing from dysplastic lesions, is the main long-term complication of pancolitis. The aims of the present study were to assess the risks for neoplasia and advanced neoplasia (AN), respectively, in ulcerative colitis (UC) and Crohn's disease (CD) patients with pancolitis, and to search for protective and risk factors for colorectal neoplasia.
METHODS: A total of 855 inflammatory bowel disease (IBD) patients with longstanding pancolitis (276 UC, 56 IBD unclassified (IBDu), and 523 CD) had pathological examination of a proctocolectomy specimen (n=255) or multiple biopsy samples from a surveillance colonoscopy (n=600) after median disease duration of 115 months. Risk factors for low-grade dysplasia (LGD) and AN, respectively, were searched for in the whole group of patients and in a case-control comparison after matching for IBD phenotype.
RESULTS: A total of 75 patients eventually developed colorectal neoplasia: 14 adenomas, 28 nonadenomatous LGD, and 33 ANs. The 25-year cumulative risks for neoplasia and AN, respectively, were 32.8±5.7% and 25.9±5.7% in UC and IBDu vs. 12.1±2.7% and 3.9±2.0% in CD (P<0.0001). In CD, patients with UC-like endoscopic appearance (n=126) had an increased risk for AN compared with those with discrete lesions (at 25 years, 10.6±7.2 vs. 1.5±0.9%). In the case-control comparison, factors associated with an increased risk of AN were primary sclerosing cholangitis (hazard ratio (HR) 4.72 (1.54-14.52)) and family history of CRC (HR 3.37 (1.02-11.14)), whereas previous segmental colectomy was protective (HR 0.25 (0.07-0.88)).
CONCLUSIONS: The risk of AN in longstanding pancolitis is higher in UC or IBDu than in CD. In CD, this risk is significantly increased in patients with UC-like endoscopic lesions. The surveillance program should focus on these latter patients.

Entities:  

Mesh:

Year:  2010        PMID: 20551939     DOI: 10.1038/ajg.2010.248

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  13 in total

1.  Point-counterpoint: Are we overtreating patients with mild ulcerative colitis?

Authors:  Akbar K Waljee; Ryan W Stidham; Peter D R Higgins; Sandeep Vijan; Sameer D Saini
Journal:  J Crohns Colitis       Date:  2013-08-12       Impact factor: 9.071

Review 2.  Large-duct cholangiopathies: aetiology, diagnosis and treatment.

Authors:  Shyam Menon; Andrew Holt
Journal:  Frontline Gastroenterol       Date:  2019-01-04

Review 3.  Impact of medical therapies on inflammatory bowel disease complication rate.

Authors:  Catherine Reenaers; Jacques Belaiche; Edouard Louis
Journal:  World J Gastroenterol       Date:  2012-08-07       Impact factor: 5.742

4.  miR-4728-3p Functions as a Tumor Suppressor in Ulcerative Colitis-associated Colorectal Neoplasia Through Regulation of Focal Adhesion Signaling.

Authors:  Joel Pekow; Alan L Hutchison; Katherine Meckel; Kymberly Harrington; Zifeng Deng; Nitya Talasila; David T Rubin; Stephen B Hanauer; Roger Hurst; Konstantin Umanskiy; Alessandro Fichera; John Hart; Aaron R Dinner; Marc Bissonnette
Journal:  Inflamm Bowel Dis       Date:  2017-08       Impact factor: 5.325

5.  The histopathological approach to inflammatory bowel disease: a practice guide.

Authors:  Cord Langner; Fernando Magro; Ann Driessen; Arzu Ensari; Gerassimos J Mantzaris; Vincenzo Villanacci; Gabriel Becheanu; Paula Borralho Nunes; Gieri Cathomas; Walter Fries; Anne Jouret-Mourin; Claudia Mescoli; Giovanni de Petris; Carlos A Rubio; Neil A Shepherd; Michael Vieth; Rami Eliakim; Karel Geboes
Journal:  Virchows Arch       Date:  2014-02-01       Impact factor: 4.064

6.  Oncological outcomes of IBD-associated versus sporadic colorectal cancer in modern era: a matched case-control study.

Authors:  Antoine Thicoïpé; David Laharie; Denis Smith; Edouard Chabrun; Anne Rullier; Florian Poullenot; Eric Rullier; Quentin Denost
Journal:  Int J Colorectal Dis       Date:  2018-04-19       Impact factor: 2.571

7.  Colorectal cancer surveillance in patients with inflammatory bowel disease: What is new?

Authors:  Danila Guagnozzi; Alfredo J Lucendo
Journal:  World J Gastrointest Endosc       Date:  2012-04-16

8.  Ameliorating Active Ulcerative Colitis via an Orally Available Toll-Like Receptor-9 Modifier: A Prospective Open-Label, Multicenter Phase II Trial.

Authors:  Iris Dotan; Etgar Levy-Nissenbaum; Yehuda Chowers; Alexander Fich; Eran Israeli; Tomer Adar; Shimon Shteingart; Hermona Soreq; Eran Goldin
Journal:  Dig Dis Sci       Date:  2016-08-29       Impact factor: 3.199

Review 9.  Worldwide Incidence of Colorectal Cancer, Leukemia, and Lymphoma in Inflammatory Bowel Disease: An Updated Systematic Review and Meta-Analysis.

Authors:  Chelle L Wheat; Kindra Clark-Snustad; Beth Devine; David Grembowski; Timothy A Thornton; Cynthia W Ko
Journal:  Gastroenterol Res Pract       Date:  2016-05-16       Impact factor: 2.260

10.  Increased mucosal expression of miR-215 precedes the development of neoplasia in patients with long-standing ulcerative colitis.

Authors:  Joel Pekow; Katherine Meckel; Urszula Dougherty; Haider I Haider; Zifeng Deng; John Hart; David T Rubin; Marc Bissonnette
Journal:  Oncotarget       Date:  2018-04-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.